NCT05222984 2026-04-20
Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax
City of Hope Medical Center
Phase 1 Active not recruiting
Clinical Trials
40 trialsNCT01989585 2026-04-13
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT04472598 2026-03-23
TRANSFORM-1
AbbVie
Phase 3 Completed
NCT05455294 2026-01-28
Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT04468984 2026-01-09
TRANSFORM-2
AbbVie
Phase 3 Active not recruiting
NCT05564650 2025-12-08
Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome
Thomas Jefferson University
Phase 1 Active not recruiting
NCT02079740 2025-09-30
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT05192889 2025-09-22
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
St. Jude Children's Research Hospital
Phase 1/2 Active not recruiting
NCT04454658 2025-07-16
Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis
AbbVie
Phase 1 Active not recruiting
NCT00788684 2025-02-20
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
AbbVie
Phase 1 Completed
NCT04041050 2025-02-14
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
AbbVie
Phase 1 Active not recruiting
NCT02143401 2024-11-22
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT05358639 2024-11-18
Combination of Olaparib and Navitoclax in Women with HGSC and TNBC
Sunnybrook Health Sciences Centre
Phase 1 Active not recruiting
NCT02520778 2024-08-21
Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT06007911 2024-08-13
Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Medical College of Wisconsin
Phase 1 Withdrawn
NCT05740449 2024-06-21
HEM-iSMART A
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Withdrawn
NCT06210750 2024-05-17
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT03366103 2023-10-17
Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT04480086 2023-08-29
Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis
AbbVie
Phase 1 Terminated
NCT00481091 2023-06-13
A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
AbbVie
Phase 1/2 Completed
NCT03181126 2021-10-14
A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma
AbbVie
Phase 1 Completed
NCT05054465 2021-09-23
ITALLI001
Israeli Medical Association
Phase 1/2 Not yet recruiting
NCT00406809 2021-08-02
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
AbbVie
Phase 1/2 Completed
NCT02591095 2019-03-19
MONAVI-1
Centre Francois Baclesse
Phase 2 Completed
NCT00445198 2018-06-06
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
AbbVie
Phase 1/2 Completed
NCT00878449 2018-06-06
A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer
AbbVie
Phase 1 Completed
NCT00887757 2017-11-21
Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors
AbbVie
Phase 1 Completed
NCT00891605 2017-11-21
Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors
AbbVie
Phase 1 Completed
NCT00982566 2017-11-21
Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer
AbbVie
Phase 1 Completed
NCT01121133 2017-11-21
A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax
AbbVie
Phase 1 Completed
NCT01009073 2017-11-20
A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects
AbbVie
Phase 1 Completed
NCT01828476 2017-05-04
Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT01087151 2016-11-02
A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)
Genentech, Inc.
Phase 2 Completed
NCT01423539 2016-11-02
NAVIGATE
Genentech, Inc.
Phase 2 Withdrawn
NCT01557777 2014-07-04
Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)
AbbVie
Phase 2 Completed
NCT00868413 2013-06-07
Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
AbbVie
Phase 1 Completed
NCT00888108 2012-05-22
Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With Cancer
Abbott
Phase 1 Completed
NCT01021358 2010-12-20
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).
Abbott
Phase 1 Completed
NCT00743028 2010-10-07
Assess the Oral Bioavailability of New ABT-263 Formulations
Abbott
Phase 1 Completed
NCT00918450 2010-02-26
Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen
Abbott
Phase 2 Withdrawn